Your browser doesn't support javascript.
loading
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Nielsen, Lene Kongsgaard; Stege, Claudia; Lissenberg-Witte, Birgit; van der Holt, Bronno; Mellqvist, Ulf-Henrik; Salomo, Morten; Bos, Gerard; Levin, Mark-David; Visser-Wisselaar, Heleen; Hansson, Markus; van der Velden, Annette; Deenik, Wendy; Coenen, Juleon; Hinge, Maja; Klein, Saskia; Tanis, Bea; Szatkowski, Damian; Brouwer, Rolf; Westerman, Matthijs; Leys, Rineke; Sinnige, Harm; Haukås, Einar; van der Hem, Klaas; Durian, Marc; Gimsing, Peter; van de Donk, Niels; Sonneveld, Pieter; Waage, Anders; Abildgaard, Niels; Zweegman, Sonja.
Afiliação
  • Nielsen LK; Quality of Life Research Center, Department of Haematology, Odense University Hospital, Odense, Denmark lene.kongsgaard.nielsen@rsyd.dk.
  • Stege C; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Lissenberg-Witte B; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam, the Netherlands.
  • van der Holt B; HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Mellqvist UH; Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gotheborg, Sweden.
  • Salomo M; Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
  • Bos G; Department of Haematology, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
  • Visser-Wisselaar H; HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Hansson M; Department of Haematology and Wallenberg Center for Molecular Medicine, Skåne University Hospital, Lund University, Lund, Sweden.
  • van der Velden A; Department of Internal Medicine, Martini Ziekenhuis, Groningen, the Netherlands.
  • Deenik W; Department of Internal Medicine, Tergooi Ziekenhuis, Hilversum, the Netherlands.
  • Coenen J; Department of Internal Medicine, Isala, Zwolle, the Netherlands.
  • Hinge M; Department of Internal Medicine, Division of Hematology, Vejle Hospital, Vejle, Denmark.
  • Klein S; Department of Internal Medicine, Meander Medisch Centrum, Amersfoort, the Netherlands.
  • Tanis B; Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, the Netherlands.
  • Szatkowski D; Department of Oncology, Haematology and Palliative Care, Førde Central Hospital, Førde, Norway.
  • Brouwer R; Department of Internal Medicine, Reinier de Graaf Ziekenhuis, Delft, the Netherlands.
  • Westerman M; Department of Internal Medicine, Northwest Clinics, Alkmaar, the Netherlands.
  • Leys R; Department of Internal Medicine, Maasstad Ziekenhuis, Rotterdam, the Netherlands.
  • Sinnige H; Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands.
  • Haukås E; Department of Haematology, Stavanger University Hospital, Stavanger, Norway.
  • van der Hem K; Department of Internal Medicine, Zaans Medisch Centrum, Zaandam, the Netherlands.
  • Durian M; Department of Internal Medicine, Tweesteden Ziekenhuis, Tilburg, the Netherlands.
  • Gimsing P; Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
  • van de Donk N; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Sonneveld P; Department of Haematology, Erasmus Medical Center Cancer Center, Rotterdam, the Netherlands.
  • Waage A; Department of Haematology, St Olavs Hospital and Norwegian University of Science and Technology, Trondheim, Norway.
  • Abildgaard N; Quality of Life Research Center, Department of Haematology, Odense University Hospital, Odense, Denmark.
  • Zweegman S; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.
Haematologica ; 105(6): 1650-1659, 2020 06.
Article em En | MEDLINE | ID: mdl-31515355
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Talidomida / Lenalidomida / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Dinamarca
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Talidomida / Lenalidomida / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Dinamarca